Standard Chemical Pharmaceutical Stock Debt To Equity
| 1720 Stock | TWD 64.90 1.30 2.04% |
Standard Chemical Pharmaceutical fundamentals help investors to digest information that contributes to Standard Chemical's financial success or failures. It also enables traders to predict the movement of Standard Stock. The fundamental analysis module provides a way to measure Standard Chemical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Standard Chemical stock.
Standard |
Standard Chemical Pharmaceutical Company Debt To Equity Analysis
Standard Chemical's Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current Standard Chemical Debt To Equity | 25.70 % |
Most of Standard Chemical's fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Standard Chemical Pharmaceutical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
According to the company disclosure, Standard Chemical Pharmaceutical has a Debt To Equity of 25.7%. This is 52.0% lower than that of the Pharmaceuticals sector and 69.4% lower than that of the Health Care industry. The debt to equity for all Taiwan stocks is 47.23% higher than that of the company.
Standard Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Standard Chemical's direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Standard Chemical could also be used in its relative valuation, which is a method of valuing Standard Chemical by comparing valuation metrics of similar companies.Standard Chemical is currently under evaluation in debt to equity category among its peers.
Standard Fundamentals
| Return On Equity | 0.19 | |||
| Return On Asset | 0.0711 | |||
| Profit Margin | 0.15 % | |||
| Operating Margin | 0.19 % | |||
| Current Valuation | 10.56 B | |||
| Shares Outstanding | 178.7 M | |||
| Shares Owned By Insiders | 57.56 % | |||
| Shares Owned By Institutions | 1.09 % | |||
| Price To Earning | 15.72 X | |||
| Price To Book | 2.40 X | |||
| Price To Sales | 1.90 X | |||
| Revenue | 4.6 B | |||
| Gross Profit | 2.07 B | |||
| EBITDA | 1.24 B | |||
| Net Income | 706.73 M | |||
| Cash And Equivalents | 1.55 B | |||
| Cash Per Share | 8.70 X | |||
| Total Debt | 50 M | |||
| Debt To Equity | 25.70 % | |||
| Current Ratio | 1.93 X | |||
| Book Value Per Share | 25.38 X | |||
| Cash Flow From Operations | 827.03 M | |||
| Earnings Per Share | 4.54 X | |||
| Number Of Employees | 14 | |||
| Beta | 0.25 | |||
| Market Capitalization | 10.44 B | |||
| Total Asset | 10.1 B | |||
| Retained Earnings | 1.17 B | |||
| Working Capital | 1.43 B | |||
| Current Asset | 2.6 B | |||
| Current Liabilities | 1.18 B | |||
| Annual Yield | 0.04 % | |||
| Five Year Return | 3.80 % | |||
| Net Asset | 10.1 B | |||
| Last Dividend Paid | 2.5 |
About Standard Chemical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Standard Chemical Pharmaceutical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Standard Chemical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Standard Chemical Pharmaceutical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Standard Stock Analysis
When running Standard Chemical's price analysis, check to measure Standard Chemical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Standard Chemical is operating at the current time. Most of Standard Chemical's value examination focuses on studying past and present price action to predict the probability of Standard Chemical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Standard Chemical's price. Additionally, you may evaluate how the addition of Standard Chemical to your portfolios can decrease your overall portfolio volatility.